Interestingly, frankincense is arguably the most “versatile yet unconventional” botanical ingredient in human civilization.
Mentioned in the Bible as one of the three gifts presented by the Three Wise Men to Jesus Christ, it was also a valuable commodity traded along the Silk Road and depicted in Dunhuang murals. Even today, its incense is burned in churches worldwide, with believers believing its fumes bridge the mortal and divine realms. Nevertheless, few people realize that this resin steeped in religious heritage has emerged as a promising new player in the modern functional food sector and the global market for botanical raw materials studied for inflammation-related pathways.
It also bears multiple traditional Chinese aliases, including Xunluxiang, Tianzexiang and Molexiang.
Official Identity and Application Status in China
Botanically, frankincense refers to the dried resin extracted from Boswellia carterii, a plant of the Burseraceae family. Primarily cultivated in Somalia and Ethiopia, it was introduced to China via the ancient Silk Road.
Frankincense holds official legal status in China. It is recorded in the 2020 Edition of the Chinese Pharmacopoeia as a standardized traditional Chinese medicinal herb. Within the traditional Chinese medicine framework, the monograph classifies it under the classical TCM functions of "activating blood circulation" and "reducing swelling" — historical TCM categories that describe heritage usage, not modern therapeutic claims. The same classical framing appears in the Compendium of Materia Medica compiled in the Ming Dynasty: “Frankincense activates blood circulation while myrrh dissipates static blood; both are paired in classical prescriptions.”
In traditional Chinese medicine, the classic herbal combination of frankincense and myrrh is widely known as the Frankincense-Myrrh Herb Pair. One focuses on activating blood flow and relieving pain, while the other works to disperse blood stasis and reduce swelling. This synergistic pairing is widely adopted in ancient herbal formulas and remains extensively used in modern proprietary Chinese medicines.
Frankincense essential oil is a legally permitted food additive in China, listed in the Catalogue of Natural Food Flavors under GB 2760 National Food Safety Standard. It can be properly added in accordance with national food safety regulations. Featuring a mild sweet aroma mixed with unique spicy undertones, it is commonly used for flavor enhancement in baked goods, compound seasonings and flavored beverages. In addition, its natural bacteriostatic and antioxidant properties enable it to optimize food flavor and extend shelf life effectively.
Despite the booming trend of food-medicine homologous raw materials in the consumer market, frankincense has not yet been included in China’s official Food-Medicine Homologous Raw Material List. This means it cannot be directly used as a common food raw material, and its domestic application is mainly confined to pharmaceutical fields (TCM decoction pieces, proprietary Chinese medicines) and external skincare products, which forms the core development boundary distinguishing it from other approved novel food ingredients.
Furthermore, frankincense resin extracts (such as Boswellia serrata resin extract) are included in the Inventory of Existing Cosmetic Raw Materials of China, widely applied in skincare formulations for anti-aging effects.
Global Application Layout of Frankincense
Before elaborating on the mechanisms studied in pharmacological research, it is essential to clarify its global market distribution, which extends far beyond the Chinese market.
India: Mature Functional Food Market
Frankincense, locally named Sallaki, has been utilized in the ancient Ayurveda system for over a thousand years. Building on this traditional use, modern pharmacological research has investigated the resin and its constituents. At present, frankincense extract-based dietary supplements are highly mature in the Indian market, mainly positioned for joint-comfort and general wellness applications studied in published research.
Europe & America: Science-Driven Pharmaceutical Exploration
As a matter of regulatory history, the European Medicines Agency (EMA) granted an orphan-drug designation to a Boswellia extract in 2002, after which the extract was the subject of clinical research in that context. In the United States, frankincense dietary supplements are mainly developed for joint-maintenance and gut-comfort applications studied in research, positioning the ingredient as a botanical that is frequently discussed alongside curcumin in the health-product industry.
China: Dominated by Pharmaceuticals, Supplemented by Cosmetics, Functional Food Development Remains Challenging
Industry statistics show that the overall market scale of frankincense-related products (including essential oil, crude resin and standardized extracts) in China has reached billions of RMB. Its application structure is roughly divided as follows: pharmaceutical raw materials account for about 30% (TCM decoction pieces and finished medicines), cosmetics and daily chemical products take up around 25%, food flavorings and health foods occupy 15%, and the rest are used for religious rituals and industrial purposes.
A notable industrial trend is that, driven by rising worldwide demand for botanical raw materials studied for inflammation-related pathways, domestic raw material manufacturers are actively promoting the food-grade application approval of frankincense extracts, while numerous brands are developing joint-health-oriented health food products containing frankincense under official health food registration channels.
Core Functional Essence: Boswellic Acids
To understand what has been studied about frankincense, it is critical to focus on its core active constituents.
The primary bioactive compounds in frankincense resin are triterpenoid substances collectively called boswellic acids. Among them, Acetyl-11-Keto-β-Boswellic Acid (AKBA) shows the most prominent activity in pharmacological research, serving as the core evaluation index for the purity and constituent potency of high-quality frankincense extracts, which is clearly marked on premium raw material specifications.
The mechanism of AKBA studied in research is better characterized than that of most peer natural ingredients: in research it has been reported to selectively inhibit 5-lipoxygenase (5-LOX), a step in the synthesis of leukotrienes.
This targeted inhibition mechanism, as described in research, is of particular interest:
Common anti-inflammatory and analgesic agents such as NSAIDs mainly act on COX-1 and COX-2 pathways. Long-term inhibition of COX-1 is associated with gastrointestinal side effects, which is the main reason cited for gastric discomfort from long-term intake of synthetic painkillers.
By contrast, the 5-LOX pathway is independent of the COX pathway. Because boswellic acids have been studied for selective activity on the 5-LOX pathway rather than COX, they have been a frequent subject of research into osteoarthritis and intestinal inflammatory conditions.
In addition, boswellic acids have been studied for inhibition of human leukocyte elastase (HLE), an enzyme implicated in articular cartilage damage and the progression of rheumatoid arthritis. Multiple studies have also reported that boswellic acids can modulate the MAPK and NF-κB signaling pathways, which are central regulatory hubs in inflammatory responses.
Core Limitations Restricting Domestic Market Popularization
Despite its high recognition in the global functional raw material industry (especially the classic frankincense-curcumin joint-health combination widely popular in European and American markets), frankincense still enjoys low public awareness among ordinary Chinese consumers. Most people only regard it as a high-end incense raw material, without being aware of its oral-supplement applications or the joint-comfort uses studied in research. The main constraints are summarized as follows:
Cognitive Barriers Brought by Naming
In Chinese public cognition, the term “frankincense” is closely associated with religious rituals and aromatherapy, making it difficult for consumers to link it with functional health raw materials. In contrast, ingredient names like curcumin, quercetin and resveratrol are more in line with public cognition of scientific functional components, easily gaining initial consumer attention.
Strict Regulatory Restrictions on Application Scenarios
As mentioned above, frankincense is not included in China’s food-medicine homologous catalogue, leading to narrower food application channels compared with approved raw materials such as curcumin and ginkgo leaf extracts. Downstream brands face complicated approval procedures and high compliance costs when developing frankincense-based functional foods, an insurmountable institutional barrier that cannot be broken through merely by market popularization.
Defective Natural Bioavailability
Boswellic acids, especially AKBA, feature poor water solubility and low oral absorption rate, a common drawback of most natural plant active ingredients. This directly leads to weak perceived efficacy among end consumers, severely damaging product market reputation. The industry has developed multiple solutions including microencapsulation, phospholipid complexation and nanoemulsion delivery technologies to boost bioavailability. Patented high-efficiency extracts such as 5-Loxin and AprèsFlex have been evaluated in clinical research, yet they come with higher raw material costs. Currently, domestic frankincense products are uneven in quality with huge gaps in AKBA content, making it hard for consumers to distinguish high-quality products.
Lack of Leading Brands for Category Popularization
Glucosamine and chondroitin dominate the domestic joint health market, while calcium supplements have formed solid consumption cognition among middle-aged and elderly groups. As a differentiated ingredient studied for inflammation-related pathways but with low popularity, frankincense requires sustained capital investment and systematic public science popularization to build independent category cognition.
Promising Development Opportunities for Frankincense
In spite of existing drawbacks, frankincense still holds enormous market breakout potential amid the current industry trend:
Incremental Market Demand in Joint Health Track
Accelerated population aging and the booming national fitness trend have continuously expanded the consumer group concerned with joint comfort. Modern consumers are no longer satisfied with simple joint nutrient supplementation, showing strong willingness to try natural targeted ingredients studied for inflammation-related pathways, creating a favorable market entry window for frankincense.
Differentiated Competitive Edge via 5-LOX Inhibition Mechanism
Most mainstream joint-care ingredients including glucosamine, chondroitin and curcumin are associated with diverse pathways in research. The 5-LOX-targeted mechanism studied for frankincense is well documented in academic research, which can form a distinct core selling point once accurately communicated to consumers.
Synergistic Combination with Curcumin Becomes the Fastest Popularization Path
Clinical studies have investigated the combined use of boswellic acids and curcumin, which have been studied for activity on different inflammatory pathways. This classic compound formula has achieved great market success in overseas markets, and similar health food formulations have gradually emerged in China. Developing compound products based on mature matching formulas can greatly reduce consumer education costs compared with launching single new ingredients.
Underrated Development Potential in Cosmetic Field
Frankincense essential oil has long been applied in aromatherapy and high-end skincare products. The soothing properties studied in research make it of interest for skincare segments such as sensitive-skin care and acne-prone skin conditioning. This track features lower market competition intensity than oral health products, enabling early entrants to seize first-mover advantages.
Boasting thousands of years of practical application history, mechanisms studied in pharmacological research, dual theoretical support from Ayurveda traditional practice and modern pharmacology, plus mature large-scale commercial application experience worldwide, frankincense has solid inherent advantages. However, restricted by domestic regulatory boundaries, application thresholds and inherent bioavailability defects, it has failed to step into the mainstream of domestic functional raw materials.
It is expected that frankincense will break away from its current developmental dilemma in the future and fully unleash its tremendous industrial value.
References
-
Ernst E. Frankincense: systematic review[J]. BMJ Complementary Medicine, 2008.
-
European Medicines Agency (EMA). Orphan drug designation of Boswellia extract for peritumoral brain edema treatment, 2002.
-
Yu G P, et al. Effectiveness of Boswellia and Boswellia extract for osteoarthritis patients: a systematic review and meta-analysis[J]. BMC Complementary Medicine and Therapies, 2020.
-
National Pharmacopoeia Commission. The 2020 Edition of Chinese Pharmacopoeia (Volume I), Crude Drug Standard of Frankincense.